Analyst Price Targets — VNDA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 11:09 am | — | H.C. Wainwright | $24.00 | $8.48 | TheFly | Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright |
| January 5, 2026 11:05 am | — | H.C. Wainwright | $22.00 | $8.25 | TheFly | Vanda Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright |
| December 31, 2025 10:04 am | — | Jefferies | $7.50 | $7.03 | TheFly | Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies |
| November 5, 2025 7:42 am | Madison El-Saadi | B.Riley Financial | $11.00 | $4.35 | StreetInsider | B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy |
| July 11, 2024 6:12 am | Charles Duncan | Cantor Fitzgerald | $11.00 | $5.21 | TheFly | Vanda Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
Latest News for VNDA
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m.
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are up during Wednesday's premarket session following the FDA's approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, as well as the company's rare skin disease drug is under FDA review.
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026. GPP is a rare, chronic, life-threatening autoinflammatory skin disorder…
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of some unusual options trading activity on Monday. Traders purchased 13,610 call options on the stock. This is an increase of approximately 596% compared to the typical volume of 1,955 call options. Vanda Pharmaceuticals Trading Up 41.5% Shares of Vanda Pharmaceuticals stock opened at
Vanda Pharmaceuticals Inc. has received FDA approval for BYSANTI, a new atypical antipsychotic targeting bipolar I disorder and schizophrenia. VNDA now markets five products, but BYSANTI's differentiation from Fanapt is questioned due to similar active molecules and looming patent expiry. 2025 saw Fanapt sales up 24%, but VNDA posted a $(220.5m) net loss and expects higher cash burn in 2026, raising funding concerns.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VNDA.
U.S. House Trading
No House trades found for VNDA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.